StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Eli Lilly & Co. (LLY) Could be the Beneficiary of Pfizer's (PFE) Ibrance Setback - Goldman Sachs
June 1, 2020 7:56 AM
Goldman Sachs analyst, Terence Flynn, believes Eli Lilly & Co. (NYSE: LLY) is likely to be the beneficiary from Pfizer's ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Hot Comments
Next Articles
Pfizer (PFE) PT Lowered to $39 at Wolfe Research
June 1, 2020 8:36 AM